Archive | C17 Funded Research RSS for this section

The INUIT CANCER EXPERIENCE depicted in “Jon’s Tricky Journey” (storybook+ educational resource) by Pat McCarthy, and funded by C17 with CCCF. All sites to receive copies. See full posting for book website with previews of this stunning book.

From the author, Pat McCarthy:

 

Hello everyone! This is my first e-mail blast to family, friends and colleagues. I wanted to let you know that my book has been published by Inhabit Media and is available on Amazon.com (US),  and on Indigo books (Canada). The amazon and indigo websites say release date of Sept 1 2017, however the books should be arriving in the Inhabit Media warehouse this week, and will be available sooner. The book is bilingual; English and Inuktitut.

My website is:  www.jonstrickyjourney.vistaprintdigital.com

Inhabit Media website:  http://inhabitmedia.com/2017/06/05/jons-tricky-journey/

This book was supported with a grant from C17,  in partnership with Childhood Cancer Canada Foundation, and with support from the Children’s Hospital of Eastern Ontario.


Jon loves his life in the North. But when he feels a pain that won’t go away, he must go to a children’s hospital in the south to find out what is wrong. A doctor there tells Jon he has cancer and will have to stay at the hospital for a while.

Suddenly Jon’s life is upside down! But with a handful of tricks from the doctors and nurses, and new friends, Jon discovers ways to cope with some of the tricky parts of having cancer.

Accompanied by a resource guide for parents and caregivers, including hospital and support information, Jon’s Tricky Journey opens a conversation between Inuit children facing a cancer diagnosis and their families to help make a difficult and confusing time more manageable.

Written by Patricia McCarthy | Illustrated by Hwei Lim

ISBN: 978-1-77227-145-4 | $19.95 | 8.5″ x 8.5″ | 70 pages | Full-colour illustrations | Paperback | Bilingual Inuktitut and English

Ages 5–7

Advertisements

Congratulate Henrique Bittencourt and Jason Berman on their recently awarded C17 Research Network grants, funded in partnership with CCCF and ECFC

Henrique Bittencourt from CHU Ste Justine was awarded  $120,000 for his grant entitled “Third-party Human Umbilical Cord Perivascular (HUCPVC)-derived Mesenchymal Stromal Cells (MSC) to Treat Refractory or Steroid-dependent Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation in Children, TUMS Phase I-II trial”.

Jason Berman from IWK was awarded $99,930 for his grant entitled “Stromal Antigen 2 (STAG2): A novel metastatic pathway in Ewing sarcoma”

Congratulate Mark Gauthier, Trang Hoang, Bernard Jasmin and Jane McGlade–recipients of pediatric oncology operating grants funded in partnership with the Cancer Research Society

We are excited to announce the recipients of the 4 pediatric oncology grants funded in partnership with the Cancer Research Society (listed below).  These grants are each funded at $120,000 over 2 years, with C17 and CRS contributing equal funds, and are administered through the CRS.

  • Mark A Gauthier, Institut National de la Recherche Scientifique (INRS)–Second generation molecular sieving coatings using asparaginase for improved treatment of leukemia
  • Trang Hoang, Institute for Research in Immunology and Cancer/Université de Montréal–Effect of UM011997 on human T-acute lymphoblastic leukemia
  • Bernard Jasmin, University of Ottawa–Misregulation of the RNA-binding protein Staufen1 in Rhabdomyosarcoma: Impact for pathogenesis and as a novel therapeutic target
  • Jane McGlade, The Hospital for Sick Children–SLAP adaptor regulation of Cbl and tyrosine kinase signaling in leukemia

Additional information about the 2015 CRS Operating Grant Competition can be found at: http://www.crs-src.ca/2015-competition-results

Congratulations to C17 Grant Recipients: William Foulkes, Faisal Khan and Tal Schechter

The C17 Research Network is pleased to announce the recipients of the 2014/15 grant competition.

PI: Dr. William Foulkes (McGill)
Title: Towards a pan-Canadian DICER1 clinical and research network

Inherited mutations in the gene DICER1 have been discovered to cause rare types of tumours that occur primarily very early in an infant’s life, but little is known about how these mutations cause tumours. The purpose of the proposed study is to establish a network of physicians, pathologists and researchers with knowledge of DICER1-related cancers from across Canada to enable them to share valuable resources such as patient samples and treatment information. The benefits of this network will be twofold: first, it will allow the identification of most Canadian families with family members that may suffer from a DICER1-related cancer. This will provide these families with access to genetic testing and counselling, and increased surveillance for as yet unaffected infants. Second, collecting samples and information from DICER1 patients will provide researchers access to very valuable materials and information that can be used to better understand how these mutations lead to cancer development and potentially better ways to treat affected individuals. The network will create a link between the physicians who treat patients and the researchers who work at understanding the disease, to the benefit of all.

PI: Dr. Faisal M. Khan (Alberta Children’s Hospital Research Institute)
Title: Genetic Profiling of Killer Immunoglobulin-Like Receptors (KIRs) of Natural Killer Cells as Predictors of ATG-Conditioned HLA-matched Pediatric Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes

Bone marrow transplantation (BMT) is a life-saving treatment for childhood and adult blood cancers and other blood disorders. However, BMT is toxic, especially due to ensuing hostile attack of graft cells on patient’s tissues (known as graft-vs-host disease, GVHD) or infections, and relapse of cancer. Despite of using donors matched for important immunity affecting genes, BMT is truly beneficial for only ~35% patients. Remaining 65% of patients either die due to relapse, GVHD or infections or suffer long-term due to GVHD. It is therefore important to find other gene systems that can improve BMT outcomes by controlling bad immunity (one that leads to GVHD) and/or by enhancing good immunity (one that fight cancer and infections).

Present study is focused on one such gene system known as ‘KIR’ that dictate the functioning of one of the first type of blood cells that recovers back after BMT. Here, we will assess whether presence/matching of certain KIR genes in donor and recipients lead to improved outcome of pediatric BMT. If yes, we will further refine the KIR gene assessment so that for each pediatric BMT recipient a donor can be chosen that gives the lowest likelihood of complications. This should lead to improved survival and quality of life of pediatric BMT patients.

PI: Dr. Tal Schechter (Hospital for Sick Children)

Title: A population-based study of long-term outcomes in survivors of allogeneic hematopoietic stem cell transplantation during childhood, adolescence or young adulthood

With modern therapies, more patients who are treated with bone-marrow transplantation (BMT) will continue to survive. Unfortunately, a majority of the survivors will develop long-term side effects of their transplant and related therapies. These late-effects are often severe and can lead to premature death. There are very few publications addressing late-effects after receiving a BMT in childhood. There is even less knowledge on these long-term outcomes after BMT in adolescents and young adults or in patients who underwent BMT for indications other than cancer.

Our research group has extensive experience in the investigation of late complications. In the proposed study, we plan to estimate the risk of late death and the development of subsequent cancer in children, adolescents and young adults who underwent BMT. We also plan to evaluate other health consequences in long-term survivors of childhood, adolescent and young adulthood BMT by assessing parameters such as outpatient clinic visits, and the frequency of hospitalizations. The proposed work is the foundation required to estimate the specific health burden and inform patients and health-care providers regarding the actual risk for late effects. It will also allow to plan for life long risk-based survivor care in young patients who underwent BMT.

C17 Education Webinar: Central Venous Line Dysfunction as a Predictor of Thromboembolism in Children with Cancer – Dr. Uma Anthale

Wednesday June 17, 2015 12:00-1:00 pm MST 

Objectives:

  1. To review potential predictors of thromboembolism in children with cancer and CVLs.
  2. To review complications of CVL dysfunction.
  3. To review study progress to date.

Evaluation and Credit Certification:

Please fill out an evaluation form, available here.   In addition to providing feedback this form is used for attendance and to obtain credit certification.  For credit certification the form must be signed.  Submit the complete form to mjohnson@cheo.on.ca  or fax 613-738-4828

The C17 Educational Videoconferences is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada.

Webcast and Telehealth Registration:

http://webcast.otn.ca/   (The event will be listed under “Public” & “Live”, no registration required)

Book a room with your institution’s Videoconference Department, contact Bryan Makara, Manager, Telemedicine  makara@cheo.on.ca.  

Sites in Ontario can have their telemedicine contact register for the videoconference here: https://schedule.otn.ca/tsm/portal/nonclinical/details.do?request.requestId=41930282